Michael V Mazya1, Kennedy R Lees2, David Collas2, Viiu-Marika Rand2, Robert Mikulik2, Danilo Toni2, Nils Wahlgren2, Niaz Ahmed2. 1. From the Department of Neurology (M.V.M., N.W., N.A.), Karolinska University Hospital, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Acute Stroke Unit & Cerebrovascular Clinic (K.R.L.), Institute of Cardiovascular & Medical Sciences, University of Glasgow; Stroke Unit (D.C.), Watford General Hospital, UK; Department of Neurology (V.-M.R.), North Estonia Medical Centre, Tallinn, Estonia; International Clinical Research Center and Department of Neurology (R.M.), St. Anne's University Hospital, Brno, Czech Republic; and Department of Neurology and Psychiatry (D.T.), Sapienza University of Rome, Italy. michael.mazya@karolinska.se. 2. From the Department of Neurology (M.V.M., N.W., N.A.), Karolinska University Hospital, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Acute Stroke Unit & Cerebrovascular Clinic (K.R.L.), Institute of Cardiovascular & Medical Sciences, University of Glasgow; Stroke Unit (D.C.), Watford General Hospital, UK; Department of Neurology (V.-M.R.), North Estonia Medical Centre, Tallinn, Estonia; International Clinical Research Center and Department of Neurology (R.M.), St. Anne's University Hospital, Brno, Czech Republic; and Department of Neurology and Psychiatry (D.T.), Sapienza University of Rome, Italy.
Abstract
OBJECTIVE: To study the safety of off-label IV thrombolysis in patients with very severe stroke (NIH Stroke Scale [NIHSS] scores >25) compared with severe stroke (NIHSS scores 15-25), where treatment is within European regulations. METHODS: Data were analyzed from 57,247 patients with acute ischemic stroke receiving IV tissue plasminogen activator in 793 hospitals participating in the Safe Implementation of Thrombolysis in Stroke (SITS) International Stroke Thrombolysis Registry (2002-2013). Eight hundred sixty-eight patients (1.5%) had NIHSS scores >25 and 19,995 (34.9%) had NIHSS scores 15-25. Outcome measures were parenchymal hemorrhage, symptomatic intracerebral hemorrhage, mortality, and functional outcome. RESULTS: Parenchymal hemorrhage occurred in 10.7% vs 11.0% (p = 0.79), symptomatic intracerebral hemorrhage per SITS-MOST (SITS-Monitoring Study) in 1.4% vs 2.5% (p = 0.052), death at 3 months in 50.4% vs 26.9% (p < 0.001), and functional independence at 3 months in 14.0% vs 29.0% (p < 0.001) of patients with NIHSS scores >25 and NIHSS scores 15-25, respectively. Multivariate adjustment did not change findings from univariate comparisons. Posterior circulation stroke was more common in patients with NIHSS scores >25 (36.2% vs 7.4%, p < 0.001), who were also more often obtunded or comatose on presentation (58.4% vs 7.1%, p < 0.001). Of patients with NIHSS scores >25, 26.2% were treated >3 hours from symptom onset vs 14.5% with NIHSS scores of 15-25. CONCLUSIONS: Our data show no excess risk of cerebral hemorrhage in patients with NIHSS score >25 compared to score 15-25, suggesting that the European contraindication to IV tissue plasminogen activator treatment at NIHSS levels >25 may be unwarranted. Increased mortality and lower rates of functional independence in patients with NIHSS score >25 are explained by higher stroke severity, impaired consciousness on presentation due to posterior circulation ischemia, and longer treatment delays.
OBJECTIVE: To study the safety of off-label IV thrombolysis in patients with very severe stroke (NIH Stroke Scale [NIHSS] scores >25) compared with severe stroke (NIHSS scores 15-25), where treatment is within European regulations. METHODS: Data were analyzed from 57,247 patients with acute ischemic stroke receiving IV tissue plasminogen activator in 793 hospitals participating in the Safe Implementation of Thrombolysis in Stroke (SITS) International Stroke Thrombolysis Registry (2002-2013). Eight hundred sixty-eight patients (1.5%) had NIHSS scores >25 and 19,995 (34.9%) had NIHSS scores 15-25. Outcome measures were parenchymal hemorrhage, symptomatic intracerebral hemorrhage, mortality, and functional outcome. RESULTS: Parenchymal hemorrhage occurred in 10.7% vs 11.0% (p = 0.79), symptomatic intracerebral hemorrhage per SITS-MOST (SITS-Monitoring Study) in 1.4% vs 2.5% (p = 0.052), death at 3 months in 50.4% vs 26.9% (p < 0.001), and functional independence at 3 months in 14.0% vs 29.0% (p < 0.001) of patients with NIHSS scores >25 and NIHSS scores 15-25, respectively. Multivariate adjustment did not change findings from univariate comparisons. Posterior circulation stroke was more common in patients with NIHSS scores >25 (36.2% vs 7.4%, p < 0.001), who were also more often obtunded or comatose on presentation (58.4% vs 7.1%, p < 0.001). Of patients with NIHSS scores >25, 26.2% were treated >3 hours from symptom onset vs 14.5% with NIHSS scores of 15-25. CONCLUSIONS: Our data show no excess risk of cerebral hemorrhage in patients with NIHSS score >25 compared to score 15-25, suggesting that the European contraindication to IV tissue plasminogen activator treatment at NIHSS levels >25 may be unwarranted. Increased mortality and lower rates of functional independence in patients with NIHSS score >25 are explained by higher stroke severity, impaired consciousness on presentation due to posterior circulation ischemia, and longer treatment delays.
Authors: Hakan Sarikaya; Marcel Arnold; Stefan T Engelter; Philippe A Lyrer; Heinrich P Mattle; Dimitrios Georgiadis; Leo H Bonati; Felix Fluri; Urs Fischer; Oliver Findling; Pietro Ballinari; Ralf W Baumgartner Journal: Stroke Date: 2011-07-21 Impact factor: 7.914
Authors: Niaz Ahmed; Nils Wahlgren; Martin Grond; Michael Hennerici; Kennedy R Lees; Robert Mikulik; Mark Parsons; Risto O Roine; Danilo Toni; Peter Ringleb Journal: Lancet Neurol Date: 2010-07-26 Impact factor: 44.182
Authors: Wouter J Schonewille; Christine A C Wijman; Patrik Michel; Christina M Rueckert; Christian Weimar; Heinrich P Mattle; Stefan T Engelter; David Tanne; Keith W Muir; Carlos A Molina; Vincent Thijs; Heinrich Audebert; Thomas Pfefferkorn; Kristina Szabo; Perttu J Lindsberg; Gabriel de Freitas; L Jaap Kappelle; Ale Algra Journal: Lancet Neurol Date: 2009-07-03 Impact factor: 44.182
Authors: W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas Journal: Lancet Date: 1998-10-17 Impact factor: 79.321
Authors: Nils Wahlgren; Niaz Ahmed; Niclas Eriksson; Franz Aichner; Erich Bluhmki; Antoni Dávalos; Terttu Erilä; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Martin Köhrmann; Vincent Larrue; Kennedy R Lees; Thomas Machnig; Risto O Roine; Danilo Toni; Geert Vanhooren Journal: Stroke Date: 2008-10-16 Impact factor: 7.914
Authors: Jorge Pagola; Marc Ribo; José Alvarez-Sabin; Marta Rubiera; Estevo Santamarina; Olga Maisterra; Raquel Delgado-Mederos; Gemma Ortega; Manuel Quintana; Carlos A Molina Journal: J Neuroimaging Date: 2011-04 Impact factor: 2.486
Authors: W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne Journal: JAMA Date: 1995-10-04 Impact factor: 56.272
Authors: Xia Wang; Thompson G Robinson; Tsong-Hai Lee; Qiang Li; Hisatomi Arima; Philip M Bath; Laurent Billot; Joseph Broderick; Andrew M Demchuk; Geoffrey Donnan; Jong S Kim; Pablo Lavados; Richard I Lindley; Sheila O Martins; Veronica V Olavarria; Jeyaraj D Pandian; Mark W Parsons; Octavio M Pontes-Neto; Stefano Ricci; Vijay K Sharma; Nguyen H Thang; Ji-Guang Wang; Mark Woodward; Craig S Anderson; John Chalmers Journal: JAMA Neurol Date: 2017-11-01 Impact factor: 18.302
Authors: Michael V Mazya; Charith Cooray; Kennedy R Lees; Danilo Toni; Gary A Ford; Michal Bar; Senta Frol; Tiago Moreira; Lakshmanan Sekaran; Viktor Švigelj; Nils Wahlgren; Niaz Ahmed Journal: Eur Stroke J Date: 2017-11-29
Authors: Louise E Craig; Sandy Middleton; Helen Hamilton; Fern Cudlip; Victoria Swatzell; Andrei V Alexandrov; Elizabeth Lightbody; Dame Caroline Watkins; Sheeba Philip; Dominique A Cadilhac; Elizabeth McInnes; Simeon Dale; Anne W Alexandrov Journal: Interv Neurol Date: 2018-09-25
Authors: David J Seiffge; Maurizio Paciaroni; Duncan Wilson; Masatoshi Koga; Kosmas Macha; Manuel Cappellari; Sabine Schaedelin; Clare Shakeshaft; Masahito Takagi; Georgios Tsivgoulis; Bruno Bonetti; Bernd Kallmünzer; Shoji Arihiro; Andrea Alberti; Alexandros A Polymeris; Gareth Ambler; Sohei Yoshimura; Michele Venti; Leo H Bonati; Keith W Muir; Hiroshi Yamagami; Sebastian Thilemann; Riccardo Altavilla; Nils Peters; Manabu Inoue; Tobias Bobinger; Giancarlo Agnelli; Martin M Brown; Shoichiro Sato; Monica Acciarresi; Hans Rolf Jager; Paolo Bovi; Stefan Schwab; Philippe Lyrer; Valeria Caso; Kazunori Toyoda; David J Werring; Stefan T Engelter; Gian Marco De Marchis Journal: Ann Neurol Date: 2019-04-30 Impact factor: 10.422
Authors: Irene Escudero-Martinez; Michael Mazya; Christine Teutsch; Norbert Lesko; Zuzana Gdovinova; Leonardo Barbarini; Waldemar Fryze; Michal Karlinski; Adam Kobayashi; Georgi Krastev; Ana Paiva Nunes; Katarina Pasztoova; André Peeters; Piotr Sobolewski; Aleksandras Vilionskis; Danilo Toni; Niaz Ahmed Journal: BMJ Open Date: 2020-05-19 Impact factor: 2.692